Auteur/autrice : Gilles Petitot

Oncovita, winner of the « Innovations in biotherapies and biomanufacturing » call for projects, will benefit from €4.5 million in funding under the France 2030 investment plan, and has completed a €3.5 million round of financing from private investors to support the development of its MVdeltaC immunotherapeutic vaccine in oncology. Voir la version française  

October, 2023 Abstract   The measles vaccine (MV) delivery platform has undergone development from preclinical to clinical stages, demonstrating its ability to adapt rapidly and effectively to different pathogens. The live pediatric MV holds extensive history of safety and efficacy, along with its established large-scale manufacturing capacity. To further